Late last week, Millennium Pharmaceuticals (nasdaq: MLNM - news - people ) disclosed in a regulatory filing that MLN-02, a treatment for Crohn's disease, was effective in a mid-stage clinical trial.

FORBES: Genentech's Winning Streak